Generic name: EXENATIDE 2mg in 0.65mL
Dosage form: injection, suspension, extended release
Medically reviewed on April 2, 2018.
The recommended dose of BYDUREON is 2 mg subcutaneously once every 7 days (weekly). The dose can be administered at any time of day, with or without meals.
The day of weekly administration can be changed if necessary as long as the last dose was administered 3 or more days before the new day of administration.
If a dose is missed, administer the dose as soon as noticed, provided the next regularly scheduled dose is due at least 3 days later. Thereafter, patients can resume their usual dosing schedule of once every 7 days (weekly).
If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, do not administer the missed dose and instead resume BYDUREON with the next regularly scheduled dose.
- There are two presentations of BYDUREON (i.e., a single dose tray and a single dose pen) [see How Supplied/Storage and Handling (16)]. The BYDUREON “Instructions for Use” for each presentation contains detailed instructions on the preparation and administration of BYDUREON [see Instructions for Use].
- Each presentation of BYDUREON requires constitution prior to use to obtain a final concentration of 2 mg of exenatide per 0.65 mL of suspension.
- BYDUREON is intended for patient self-administration. Prior to initiation, train patients on proper mixing and injection technique to ensure the product is adequately mixed and a full dose is delivered.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The suspension should appear white to off-white and cloudy. (BYDUREON contains microspheres which appear as white to off-white particles). Do not use if foreign particulate matter is present or if discoloration is observed. Refer patients to the accompanying Instructions for Use for disposal information [see Instructions for Use].
- Administer BYDUREON immediately after the dose is prepared as a subcutaneous injection in the abdomen, thigh, or upper arm region. Advise patients to use a different injection site each week when injecting in the same region.
- When using BYDUREON with insulin, always administer BYDUREON and insulin as separate injections. Do not mix these medications together into a single injection. It is acceptable to inject BYDUREON and insulin in the same body region but the injections should not be adjacent to each other.
- Do not administer BYDUREON intravenously or intramuscularly.
- Refer patients to the accompanying Instructions for Use for complete administration instructions with illustrations [see Instructions for Use].
Initiating BYDUREON Therapy
Prior treatment with an immediate- or extended-release exenatide product is not required when initiating BYDUREON therapy. Discontinue an immediate- or extended-release exenatide product prior to initiation of BYDUREON.
Patients changing from immediate-release exenatide to BYDUREON may experience transient
(approximately 2 to 4 weeks) elevations in blood glucose concentrations.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Bydureon (exenatide)
- Bydureon Side Effects
- During Pregnancy
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- 228 Reviews
- Drug class: incretin mimetics
- FDA Alerts (2)